AOC3: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of AOC3. The page also collects GeneMedi's different modalities and formats products for AOC3 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the AOC3 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a member of the semicarbazide-sensitive amine oxidase family. Copper amine oxidases catalyze the oxidative conversion of amines to aldehydes in the presence of copper and quinone cofactor. The encoded protein is localized to the cell surface, has adhesive properties as well as monoamine oxidase activity, and may be involved in leukocyte trafficking. Alterations in levels of the encoded protein may be associated with many diseases, including diabetes mellitus. A pseudogene of this gene has been described and is located approximately 9-kb downstream on the same chromosome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2013]
|Gene Official Name||AOC3|
|Gene Alias||HPAO, SSAO, VAP-1, VAP1|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index|
Pre-made AOC3-specific INN-index biosimilar (antibody&conjugates)-Timolumab, vepalimomab, vapaliximab
Anti-AOC3 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-577||Pre-Made Timolumab biosimilar, Whole mAb, Anti-AOC3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody||Timolumab||AOC3||Whole mAb|
|GMP-Bios-INN-1047||Pre-Made Vepalimomab Biosimilar, Whole Mab, Anti-Aoc3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody||vepalimomab||AOC3||Whole mAb|
|GMP-Bios-INN-1046||Pre-Made Vapaliximab Biosimilar, Whole Mab, Anti-Aoc3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody||vapaliximab||AOC3||Whole mAb|
Pre-made anti-AOC3 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-AOC3 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-AOC3 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T69619-Ab||Anti-AOC3 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|